Affordable Access

Publisher Website

Microencapsulated mammalian cells for simultaneous production of VEGF165b and IFNα.

Authors
Type
Published Article
Journal
Artificial cells, blood substitutes, and immobilization biotechnology
Publication Date
Volume
40
Issue
1-2
Pages
1–6
Identifiers
DOI: 10.3109/10731199.2011.560120
PMID: 22288840
Source
Medline

Abstract

Targeted and simultaneous delivery VEGF165b and IFN alpha in anti-angiogenic and other applications could offer several advantages. For this a system was design using artificial cell alginate-poly-L-lysine- alginate (APA) microcapsules. Result confirms the ability of this system for simultaneous production of these proteins for 28-days. The IFN alpha on a 3 days period increased from 8 ± 0.36 μg/ml at day 10 to 27 ± 2.4 μg/ml at day 16 and then dropped to 6.5 ± 0.5 μg/ml. The VEGF165b on a 3 days period increased from 2.7 ± 0.7 μg/ml at day 10 to 6.9 ± 1 μg/ml at day 16.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments